PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28427224-0	2017	Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.	ponatinib	0-9	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	45-51	
28427224-0	2017	Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.	ponatinib	0-9	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	52-55	
28427224-4	2017	The goal of this study was to determine whether ponatinib, an FDA-approved ABL/SRC inhibitor, reduced proliferation and/or survival of merlin-deficient human Schwann cells (HSC).	ponatinib	48-57	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	135-141	
28427224-7	2017	Ponatinib reduced merlin-deficient HSC viability in a dose-dependent manner by decreasing phosphorylation of PDGFRalpha/beta, AKT, p70S6K, MEK1/2, ERK1/2 and STAT3.	ponatinib	0-9	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	18-24	
28427224-10	2017	These results suggest that ponatinib is a potential therapeutic agent for NF2-associated schwannomas and warrants further in vivo investigation.	ponatinib	27-36	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Homo sapiens	74-77